A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19
Pedro Landete(Hospital Universitario de La Princesa), José F. Varona(Hospital Universitario HM Madrid), José Miguel Cisneros(Instituto de Salud Carlos III), Jesús Fortün(Evidence (Italy)), Fernanda Meira(PharmaMar (Spain)), Esperanza Merino(Universitat de Miguel Hernández d'Elx), Pérez Rodríguez(University Hospital Complex Of Vigo), Diego López-Mendoza(PharmaMar (Spain)), Liliana Preoțescu(Virginia Commonwealth University), Eduardo Pérez-Alba(Universidad Autónoma de Nuevo León), Pablo Ryan, Miguel Marcos(Universidad de Salamanca), Adrien Lemaignen(Centre d'Immunologie et des Maladies Infectieuses), Pablo Guisado‐Vasco(Hospital Universitario Quirónsalud Madrid), María Molina‐Molina(Instituto de Salud Carlos III), María del Carmen Fariñas-Álvarez(Universidad de Cantabria), Αnastasia Kotanidou(National and Kapodistrian University of Athens), Olga Adriana Căliman-Sturdza(Ştefan cel Mare University of Suceava), Javier Gómez(John H. Stroger, Jr. Hospital of Cook County), Carmen Hidalgo-Tenorio, Miguel Torralba(Universidad de Alcalá), José A. López-Martín(Research Institute Hospital 12 de Octubre), Paula Villares(Hospital Universitario HM Sanchinarro), Dimitar Raev, Nadia Torres(PharmaMar (Spain)), Roger Paredes(Hospital Universitari Germans Trias i Pujol), Paula Patricia García-Ocaña(Hospital Jerez Puerta del Sur), José Jimeno(European Organisation for Research and Treatment of Cancer), Elena-Maria Saiz-Lou(PharmaMar (Spain)), Mihaela-Cătălina Luca(Grigore T. Popa University of Medicine and Pharmacy), Garyphallia Poulakou, Shirley-Patricia Iglesias(University of the Coast), Vicente Estrada(Instituto de Salud Carlos III)
Cited by 16
Related Papers
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k